Benzinga's Top #PreMarket Gainers

shares rose 6.19 percent to $14.75 in pre-market trading after the company reported initiation of Phase 3 ARMOR3-SV trial of Galeterone in AR-V7 positive metastatic castration-resistant prostate cancer.

shares climbed 5.01 percent to $13.20 in pre-market trading. Nektar Therapeutics will replace

in the S&P SmallCap 600 after the close of trading on June 25.

shares climbed 4.43 percent to $65.50 in pre-market trading after dropping 1.75 percent on Tuesday.

gained 3.98 percent to $50.95 in pre-market trading after the company reported stronger-than-expected results for its fiscal second quarter.

shares rose 2.86 percent to $700.70 in pre-market trading after the company announced a 7-for-1 stock split. The split will take the form of a stock dividend payable on July 14 to holders of record at the close of business on July 2. Netflix will begin trading at the post-split price on July 15.